Education
About Us
Working with TipRanks
Follow Us
NFL Biosciences SA (DE:82F)
FRANKFURT:82F
Total Valuation
NFL Biosciences SA has a market cap or net worth of €13.50M. The enterprise value is €17.29M.
Market Cap€13.50M
Enterprise Value€17.29M
Share Statistics
NFL Biosciences SA has 12,672,242 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,672,242
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NFL Biosciences SA’s return on equity (ROE) is -2.13 and return on invested capital (ROIC) is -180.34%.
Return on Equity (ROE)-2.13
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-180.34%
Return on Capital Employed (ROCE)-2.86
Revenue Per Employee11.50
Profits Per Employee-520.21K
Employee Count4
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NFL Biosciences SA is ―. NFL Biosciences SA’s PEG ratio is 0.17.
PE Ratio―
PS Ratio421000.26
PB Ratio19.83
Price to Fair Value19.83
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.17
Income Statement
In the last 12 months, NFL Biosciences SA had revenue of 46.00 and earned -2.08M in profits. Earnings per share was -0.21.
Revenue46.00
Gross Profit-67.14K
Operating Income-2.79M
Pretax Income-2.72M
Net Income-2.08M
EBITDA-2.65M
Earnings Per Share (EPS)-0.21
Cash Flow
In the last 12 months, operating cash flow was 110.93K and capital expenditures 0.00, giving a free cash flow of 110.93K billion.
Operating Cash Flow110.93K
Free Cash Flow110.93K
Free Cash Flow per Share<0.01
Dividends & Yields
NFL Biosciences SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.78
52-Week Price Change-59.49%
50-Day Moving Average1.18
200-Day Moving Average1.33
Relative Strength Index (RSI)24.41
Average Volume (3m)0.00
Important Dates
NFL Biosciences SA upcoming earnings date is Mar 30, 2026, Before Open (Confirmed).
Last Earnings DateOct 16, 2025
Next Earnings DateMar 30, 2026
Ex-Dividend Date―
Financial Position
NFL Biosciences SA as a current ratio of 1.27, with Debt / Equity ratio of 4.20%
Current Ratio1.27
Quick Ratio1.27
Debt to Market Cap<0.01
Net Debt to EBITDA0.71
Interest Coverage Ratio-9.18K
Taxes
In the past 12 months, NFL Biosciences SA has paid -635.41K in taxes.
Income Tax-635.41K
Effective Tax Rate0.23
Enterprise Valuation
NFL Biosciences SA EV to EBITDA ratio is -6.60, with an EV/FCF ratio of 0.00.
EV to Sales380.29K
EV to EBITDA-6.60
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
NFL Biosciences SA has €3.56M in cash and marketable securities with €72.73K in debt, giving a net cash position of €3.49M billion.
Cash & Marketable Securities€3.56M
Total Debt€72.73K
Net Cash€3.49M
Net Cash Per Share€0.28
Tangible Book Value Per Share€0.08
Margins
Gross margin is 0.00%, with operating margin of -6065415.22%, and net profit margin of -4523563.04%.
Gross Margin0.00%
Operating Margin-6065415.22%
Pretax Margin-5904889.13%
Net Profit Margin-4523563.04%
EBITDA Margin-5758256.52%
EBIT Margin-5904219.57%
Analyst Forecast
The average price target for NFL Biosciences SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―